Search 

Sofinnova Ventures was founded in 1974 and is based in Menlo Park, CA. The firm has approximately $1b of assets under management, and makes life science investments from two fund families; the main Sofinnova Ventures fund and Sofinnova HealthQuest Capital. Sofinnova Venture Partners IX closed at $500 million in 2014, and the debut HealthQuest fund closed at $110 million in 2014. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. Sofinnova Ventures plans to make 4-6 new investments in life science companies in 2014. 

The Sofinnova Ventures main fund invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-30m. The fund invests in companies based in North America or Europe. 

HealthQuest Capital invests in non-biopharmaceutical life science and medtech companies and typically makes initial investments of $2-3m, with the potential for total investments of $5-6m. HealthQuest Capital is a venture growth fund focused on commercial-stage technologies, and only invests in companies headquartered in North America (particularly the US Southeast or West Coast).

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Small biotechnology companies are developing half of all future medicines, some of which may not reach patients due to lack of funding from traditional investors.

Although health-related charities received more than $31B in contributions in 2013, many of the charities which support research do not work with for-profit biotech companies. They predominantly fund academic and non-profit institutions which typically conduct early research and discover around 10% of new medicines (for-profit companies discover the remaining 90%).

Impatient is a new kind of health-related charity. We will only fund medical trials with small biotech companies.  

Our scientific advisors will select promising, unfunded, medical treatments. You choose which treatment to support and 100% of your donation is spent on testing.

If the treatment is successful, 100% of the future royalty that Impatient receives from the biotech company will support access to new medicines for people who cannot afford them.  

Joslin Diabetes Center is a foundation based in Boston, Massachusetts that was founded in 1898, and is the world's largest diabetes and clinical care organization.

Jump Capital was founded in 2012 and is based in Chicago, with an additional office in San Francisco. The firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, Jump Capital typically allocates $2-15 million, and prefers to invest in Series B-C rounds. Jump Capital invests in the USA and Canada, and has previously invested in 6 healthcare companies.

Jump Capital invests in medical devices, diagnostics, digital and mobile health, and healthcare services. The firm is open to opportunities in any clinical indication. Jump Capital is only interested in devices and diagnostics that have in-human data.

JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

Life Science Angels Inc was founded in 2004 and is based in Sunnyvale CA. The group makes early-stage equity investments in a wide range of life science companies. Life Science Angels invests primarily in California but is open to investing out of state provided a round is being syndicated with a local angel group. Life Science Angels does not rule out investing outside the USA but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied but are usually of about $2-$6, Life Science Angels usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.